|
|
|
| Clinical effect of Salvia Miltiorrhizae and Ligustrazine Injection treating cerebral thrombosis |
| ZHANG Min |
| Ward 1, Department of Neurology, Liaoyang Second People′s Hospital, Liaoning Province, Liaoyang 111000, China |
|
|
|
|
Abstract Objective To explore the clinical effect of Salvia Miltiorrhizae and Ligustrazine Injection treating cerebral thrombosis.Methods A total of 114 patients with cerebral thrombosis admitted to our hospital from June 2017 to June 2019 were selected as the research subjects.They were divided into control group and observation group according to the random number table method, 57 cases in each group.The control group was treated with conventional western medicine.The observation group was treated with Salvia Miltiorrhizae and Ligustrazine Injection.The traditional Chinese medicine (TCM) syndrome scores before and after treatment, total effective rate of treatment, and superoxide dismutase (SOD), malondialdehyde (MDA), lysophosphatidic acid (LPA), and endothelin (ET) before and after treatment were compared between the two groups.Results The total effective rate of treatment in the observation group (98.25%)was higher than that in the control group (84.21%), and the difference was statistically significant (P＜0.05).TCM syndrome score in the observation group ([8.53±1.24] points) after treatment was lower than that in the control group([12.76±1.61] points), the difference was statistically significant (P＜0.05).After treatment, the SOD content of patients in the observation group ([107.64±14.54] U/ml) was higher than that in the control group ([88.96±12.36] U/ml), MDA([5.56±0.72] μmol/L), LPA ([1.70±0.25] μmol/L), ET ([84.62±6.84] ng/L) content were lower than those in the control group ([7.89±0.94] μmol/L, [2.53±0.33] μmol/L, [120.64±10.51] ng/L), the differences were statistically significant (P＜0.05).Conclusion On the basis of conventional Western medicine treatment for patients with cerebral thrombosis, the treatment with Salvia Miltiorrhizae and Ligustrazine Injection can effectively regulate the patients′ oxidative stress response, and its application effect is significant and worthy of promotion.
|
|
|
|
|
|
| [1] |
关婷，刘佳馥，王思思.丹参川芎嗪注射液治疗脑血栓患者的临床疗效及SOD、MDA、LPA 和内皮素的作用分析[J].世界中医药，2019，14（9）：2309-2312.
|
| [2] |
倪进军，李柱.中风病中西医疗效标准的比较[J].河南中医，2001，21（5）：32-33.
|
| [3] |
高长玉，吴成翰，赵建国，等.中国脑梗死中西医结合诊治指南（2017）[J].中国中西医结合杂志，2018，38（2）：136-144.
|
| [4] |
姚莉莉，郭宝荣，许行飞.丹参川芎嗪注射液治疗椎基底动脉供血不足性眩晕的疗效观察[J].当代医学，2017，23（20）：86-87.
|
| [5] |
高阳，王桂倩，王健，等.丹参川芎嗪注射液临床应用专家共识[J].中国中药杂志，2019，44（14）：2937-2942.
|
| [6] |
曹慧敏，宋囡，张妮，等.丹参酮ⅡA 通过PI3K/Akt/mTOR信号通路调控自噬抗内皮细胞氧化应激损伤研究[J].北京中医药大学学报，2017，40（11）：933-939.
|
| [7] |
张波，伍海军，钟志军，等.丹参川芎嗪注射液对脑出血大鼠神经功能、脑水肿及神经元凋亡的影响研究[J].实用心脑肺血管病杂志，2018，26（11）：62-66.
|
| [8] |
张健，张化民.丹参川芎嗪注射液对脑梗死患者血液流变学的影响[J].中国医院用药评价与分析，2019，19（5）：588-589，593.
|
| [9] |
冯楠楠，马婷.依那普利联合丹参川芎嗪治疗老年脑血栓患者的疗效及对血浆超氧化物歧化酶和内皮素1 的影响[J].家庭医药，2017，（4）：71-72.
|
| [10] |
姜林林，马洪林，于娜，等.丹参川芎嗪注射液联合西洛他唑治疗腔隙性脑梗死患者的疗效分析[J].国际医药卫生导报，2019，25（9）：1358-1360.
|
| [11] |
孙立强.丹参川芎嗪注射液联合尤瑞克林治疗急性脑梗死的疗效观察[J].现代药物与临床，2017，32（11）：2091-2094.
|
| [12] |
薛瑶瑶，张毅.丹参川芎嗪注射液治疗脑血栓患者的临床疗效及对SOD、MDA、LPA 和内皮素的作用分析[J].世界中医药，2019，14（5）：1232-1236.
|
| [13] |
王晓瑛，王亚男，曹盼盼，等.丹参川芎嗪注射液对急性脑梗死病人血浆LPA 水平影响[J].齐鲁医学杂志，2017，32（2）：227-229.
|
| [14] |
张杰，李易易，张兆辉.溶血磷脂酸诱导PC12 细胞凋亡的机制研究[J].卒中与神经疾病，2019，26（3）：255-260.
|
| [15] |
黄海涛，叶攀.丹参川芎嗪注射液治疗脑血栓对患者脑血流动力学水平和凝血功能影响[J].时珍国医国药，2019，30（4）：917-919.
|
|
|
|
